Home » Psychology news » Seaside Therapeutics Reports Positive Data From Phase 2 Study Of STX209 In Autism Spectrum Disorders

Seaside Therapeutics Reports Positive Data From Phase 2 Study Of STX209 In Autism Spectrum Disorders

September 12, 2010 by

Seaside Therapeutics, Inc. announced positive data from an open-label Phase 2 study of STX209 conducted in patients with autism spectrum disorders (ASD)...

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>